Johnson & Johnson's (JNJ) rybrevant (amivantamab-vmjw) plus lazcluze (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical egfr-mutated non-small cell lung cancer
#JOHNSON & JOHNSON#JNJ.US#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES